EHC

SEC source: 0001127602-25-006188 · form4.xml · nonDerivative · entry 1

Tarr Mark J · CIK 0001304057 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 534,641

F1 · shares: Annual award of restricted stock pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-25-004672 · form4.xml · nonDerivative · entry 1

Price Andrew L · CIK 0001475399 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,164

F1 · price: This per share price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.29 to $98.35, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.

SEC source: 0001127602-25-001415 · form4.xml · nonDerivative · entry 2

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,632

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2024 to defer fixed percentages of their director fees for 2025. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.17 per share paid on January 15, 2025.

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $94.25 to $94.38, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-25-001394 · form4.xml · nonDerivative · entry 2

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,709

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2024 to defer fixed percentages of their director fees for 2025. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.17 per share paid on January 15, 2025.

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $94.35 to $94.41, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-25-001421 · form4.xml · nonDerivative · entry 1

Williams Terrance · CIK 0001798480 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,647

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 15, 2025, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $93.61. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-25-001415 · form4.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,257

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 15, 2025, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $93.61. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-25-001418 · form4.xml · nonDerivative · entry 1

SCHLICHTING NANCY M · CIK 0001376358 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,695

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 15, 2025, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $93.61. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-25-001413 · form4.xml · nonDerivative · entry 1

O'Connor Kevin J. · CIK 0001808321 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,429

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 15, 2025, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $93.61. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-25-001406 · form4.xml · nonDerivative · entry 1

KATZ LESLYE G · CIK 0001193884 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,105

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 15, 2025, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $93.61. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-25-001409 · form4.xml · nonDerivative · entry 1

Maryland Patricia Anne · CIK 0001798468 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,293

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 15, 2025, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $93.61. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-25-001402 · form4.xml · nonDerivative · entry 1

HERMAN JOAN E · CIK 0001248398 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,105

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 15, 2025, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $93.61. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-25-001397 · form4.xml · nonDerivative · entry 1

CARMICHAEL GREG D · CIK 0001247734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,137

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 15, 2025, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $93.61. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-25-001394 · form4.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,417

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 15, 2025, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $93.61. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-25-000305 · form4.xml · nonDerivative · entry 1

Charbonneau Elissa Joy · CIK 0001647458 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,603.061

F1 · shares: These shares were withheld or surrendered to pay the insider's tax withholding obligations incurred in connection with the vesting of the related restricted stock.

SEC source: 0001127602-25-000302 · form4.xml · nonDerivative · entry 1

COLTHARP DOUGLAS E · CIK 0001186879 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,560

F1 · shares: These shares were withheld or surrendered to pay the insider's tax withholding obligations incurred in connection with the vesting of the related restricted stock.

SEC source: 0001127602-25-000298 · form4.xml · nonDerivative · entry 1

Darby John Patrick · CIK 0001664699 · EVP, Gen Counsel & Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,856

F1 · shares: These shares were withheld or surrendered to pay the insider's tax withholding obligations incurred in connection with the vesting of the related restricted stock.

SEC source: 0001127602-25-000294 · form4.xml · nonDerivative · entry 1

Tarr Mark J · CIK 0001304057 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 522,489

F1 · shares: These shares were withheld or surrendered to pay the insider's tax withholding obligations incurred in connection with the vesting of the related restricted stock.

SEC source: 0001127602-25-000290 · form4.xml · nonDerivative · entry 1

Fay Edmund · CIK 0001433234 · Sr. Vice Pres. and Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 99,786

F1 · shares: These shares were withheld or surrendered to pay the insider's tax withholding obligations incurred in connection with the vesting of the related restricted stock.

SEC source: 0001127602-25-000287 · form4.xml · nonDerivative · entry 1

Price Andrew L · CIK 0001475399 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,206

F1 · shares: These shares were withheld or surrendered to pay the insider's tax withholding obligations incurred in connection with the vesting of the related restricted stock.

SEC source: 0001127602-24-027198 · form4.xml · nonDerivative · entry 2

COLTHARP DOUGLAS E · CIK 0001186879 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By spouse

Disclosed balance after: 65,229

F1 · kind: This transaction involved the reporting person's gift of 65,229 shares of EHC common stock to his spouse. The reporting person disclaims beneficial ownership of the securities held by his spouse, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

SEC source: 0001127602-24-027198 · form4.xml · nonDerivative · entry 1

COLTHARP DOUGLAS E · CIK 0001186879 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,998

F1 · kind: This transaction involved the reporting person's gift of 65,229 shares of EHC common stock to his spouse. The reporting person disclaims beneficial ownership of the securities held by his spouse, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

SEC source: 0001127602-24-025668 · form4.xml · nonDerivative · entry 2

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,241

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2023 to defer fixed percentages of their director fees for 2024. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.17 per share paid on October 15, 2024.

SEC source: 0001127602-24-025655 · form4.xml · nonDerivative · entry 2

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,411

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2023 to defer fixed percentages of their director fees for 2024. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.17 per share paid on October 15,2024.

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $97.62 to $97.63, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-24-025670 · form4.xml · nonDerivative · entry 1

Williams Terrance · CIK 0001798480 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,622

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2024, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $96.33. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-24-025668 · form4.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,879

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2024, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $96.33. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-24-025666 · form4.xml · nonDerivative · entry 1

SCHLICHTING NANCY M · CIK 0001376358 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,659

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2024, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $96.33. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-24-025664 · form4.xml · nonDerivative · entry 1

O'Connor Kevin J. · CIK 0001808321 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,415

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2024, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $96.33. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-24-025662 · form4.xml · nonDerivative · entry 1

Maryland Patricia Anne · CIK 0001798468 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,268

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2024, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $96.33. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-24-025660 · form4.xml · nonDerivative · entry 1

KATZ LESLYE G · CIK 0001193884 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,022

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2024, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $96.33. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-24-025657 · form4.xml · nonDerivative · entry 1

HERMAN JOAN E · CIK 0001248398 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,022

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2024, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $96.33. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-24-025655 · form4.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,128

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2024, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $96.33. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-24-025653 · form4.xml · nonDerivative · entry 4

CARMICHAEL GREG D · CIK 0001247734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,112

F2 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2024, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $96.33. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-24-022178 · form4.xml · derivative · entry 5

COLTHARP DOUGLAS E · CIK 0001186879 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Encompass Health Common Stock · 12,260 shares

Expires 2025-03-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: The exercise price and number of options reported have been adjusted, pursuant to Article 17 of the 2016 Omnibus Performance Incentive Plan, for the spin-off distribution of the common stock of Enhabit, Inc.

F3 · shares: The exercise price and number of options reported have been adjusted, pursuant to Article 17 of the 2016 Omnibus Performance Incentive Plan, for the spin-off distribution of the common stock of Enhabit, Inc.

SEC source: 0001127602-24-022178 · form4.xml · nonDerivative · entry 3

COLTHARP DOUGLAS E · CIK 0001186879 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 136,227

F2 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $87.03 to $87.04, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-24-022178 · form4.xml · nonDerivative · entry 2

COLTHARP DOUGLAS E · CIK 0001186879 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 136,325

F1 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $85.93 to $86.73, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-24-022178 · form4.xml · nonDerivative · entry 1

COLTHARP DOUGLAS E · CIK 0001186879 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 148,487

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-020568 · form4.xml · nonDerivative · entry 2

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,863

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2023to defer fixed percentages of their director fees for 2024. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.15 per share paid on July 15, 2024.

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $86.54 to $86.63, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-24-020550 · form4.xml · nonDerivative · entry 2

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,122

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2023 to defer fixed percentages of their director fees for 2024. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.15 per share paid on July 15, 2024.

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $86.61 to $86.80, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-24-020581 · form4.xml · nonDerivative · entry 1

Williams Terrance · CIK 0001798480 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,598

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2024, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $85.49. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-24-020574 · form4.xml · nonDerivative · entry 1

SCHLICHTING NANCY M · CIK 0001376358 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,624

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2024, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $85.49. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-24-020568 · form4.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,437

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2024, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $85.49. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-24-020562 · form4.xml · nonDerivative · entry 1

O'Connor Kevin J. · CIK 0001808321 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,401

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2024, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $85.49. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-24-020559 · form4.xml · nonDerivative · entry 1

Maryland Patricia Anne · CIK 0001798468 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,244

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2024, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $85.49. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-24-020555 · form4.xml · nonDerivative · entry 1

KATZ LESLYE G · CIK 0001193884 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,941

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2024, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $85.49. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-24-020552 · form4.xml · nonDerivative · entry 1

HERMAN JOAN E · CIK 0001248398 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,941

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2024, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $85.49. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-24-020550 · form4.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,788

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2024, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $85.49. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-24-020548 · form4.xml · nonDerivative · entry 1

CARMICHAEL GREG D · CIK 0001247734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,074

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2024, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $85.49. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-24-025653 · form4.xml · nonDerivative · entry 3

CARMICHAEL GREG D · CIK 0001247734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,088

F1 · shares: This acquisition is a dividend reinvestment administered by the reporting person's broker. It is eligible for deferred reporting on Form 5 pursuant to Rule 16a-6 but is being reported earlier than required on Form 4.

SEC source: 0001127602-24-016522 · form4.xml · nonDerivative · entry 1

Charbonneau Elissa Joy · CIK 0001647458 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,594.061

F1 · price: This per share price is a weighted average price. These shares were executed in multiple transactions at prices ranging from $84.96 to $85.30, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-24-014370 · form4.xml · derivative · entry 3

Darby John Patrick · CIK 0001664699 · EVP, Gen Counsel & Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Encompass Health Common Stock · 14,543 shares

Expires 2026-02-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The total share holdings reported in this column include the adjustment of outstanding restricted stock awards, pursuant to Article 17 of the 2016 Omnibus Performance Incentive Plan, for the spin-off distribution of the common stock of Enhabit, Inc.

F2 · shares: The total share holdings reported in this column include the adjustment of outstanding restricted stock awards, pursuant to Article 17 of the 2016 Omnibus Performance Incentive Plan, for the spin-off distribution of the common stock of Enhabit, Inc.